The BCL3 Knockout SK-HEP-1 Polyclonal Cells are a CRISPR/Cas9-edited cell population derived from the SK-HEP-1 human hepatic adenocarcinoma line, featuring targeted disruption of the BCL3 gene. This polyclonal knockout model provides a heterogeneous pool of edited cells that enables the study of BCL3 function within a diverse genetic background, mimicking the complexity of tumor cell populations. The CRISPR-mediated gene disruption is designed to eliminate BCL3 expression, creating a powerful loss-of-function system for investigating its roles in transcriptional regulation and disease pathways.
SK-HEP-1 cells are a widely used epithelial line isolated from the ascites of a patient with liver adenocarcinoma. They serve as a versatile model for hepatocellular carcinoma (HCC) and liver endothelial biology, combining features of both hepatic and endothelial lineages. The cells exhibit a stable epithelial morphology and are well-characterized for studies of cancer biology, including proliferation, apoptosis, and metastasis, as well as for interrogating signaling pathways relevant to liver function and pathology.
BCL3 functions as a transcriptional coactivator that specifically binds to NF-??B p50 (NFKB1) or p52 (NFKB2) homodimers, converting them from repressors to activators of gene expression. It recruits coactivator complexes containing Tip60 and histone acetyltransferases to promoter regions, facilitating transcription of target genes involved in cell cycle progression and survival, such as CCND1 and BCL2. BCL3 activity is stimulated by upstream signals including TLR4, CD40, IL-1??, and TNF??, and it integrates with key pathway components like RELA (p65), I??B?? (NFKBIA), and the IKK complex. Additionally, BCL3 interacts with regulators such as HDAC1, HDAC3, Jab1, Pirin, and ??-catenin, positioning it at the nexus of NF-??B and other signaling cascades.
In the context of SK-HEP-1 hepatocellular carcinoma cells, BCL3 knockout is particularly relevant for dissecting the molecular mechanisms underlying liver cancer progression. Aberrant BCL3 expression has been associated with enhanced proliferation, resistance to apoptosis, and metastatic potential in HCC. By ablating BCL3 in this cell line, researchers can directly examine its contribution to NF-??B?Cdriven oncogenic programs, immune evasion, and the crosstalk between tumor and stromal compartments. This model also enables investigation of BCL3’s role in inflammatory responses that fuel hepatic tumorigenesis.
This polyclonal knockout cell product is suitable for a wide array of experimental applications, including quantitative analysis of NF-??B signaling via luciferase reporter assays, assessment of cell proliferation using MTT or BrdU incorporation, and apoptosis measurement by Annexin V/PI staining. Researchers can employ RT-qPCR and western blotting to confirm gene and protein expression changes in downstream targets like MMP9 and IL-10. Functional studies may include migration and invasion assays to evaluate metastatic behavior. For further details and technical support, please contact Ascent Research.
